It uses the never-before-approved technology called messenger RNA, or mRNA, to spark an immune response in people who are vaccinated.
On a call with reporters on Tuesday, Sahin explained the significance of the news — and sent a message of hope for the world.
“I think the good message for mankind is that we now understand that COVID-19 infections can be indeed prevented by a vaccine,” he said.
Speaking to CNN on Monday, Pfizer CEO’s Albert Bourla called it “the greatest medical advance” in the last 100 years.
While the vaccine is a huge step for the scientific community, Sahin and Tureci are veterans in the world of medical achievements.
The pair, both trained physicians, established their previous company, Ganymed Pharmaceuticals, in 2001 to work on developing cancer-fighting antibodies, eventually selling it for $1.4 billion in 2016.
Chief Executive Sahin and Chief Medical Officer Tureci are listed among Germany’s 100 richest people, according to the weekly Welt am Sonntag newspaper. On Tuesday, the market value of their Nasdaq-listed company jumped to $25.72 billion — a massive leap from $4.6 billion last year.
But the couple’s charitable ethos and longstanding commitment to academia and science appear to have kept them grounded, even as their work on the Covid-19 vaccine propels them into the global spotlight.
In May, the couple told CNN they felt compelled to “provide something for society,” given the work they had done in their field over the last two decades.
Sahin was born in Iskenderun, a city on Turkey’s Mediterranean coast. He moved to Cologne, Germany when he was four, where his father worked at a local Ford factory, according to Reuters.
He met Tureci, the daughter of a Turkish physician, when the pair were both embarking on their academic careers.
Sahin and Tureci bonded over a shared passion for cancer research, according to Reuters, who reported that the couple even began their wedding day in the research lab.
In January, after reading a scientific paper about the coronavirus in Wuhan, China, Sahin was taken by the “small step” from anti-cancer mRNA drugs to mRNA-based viral vaccines, Reuters reported.
BioNTech assigned 500 of its staff to work on the project with several potential mRNA compounds, eventually closing a partnership with Pfizer in March.
Their Covid-19 vaccine approach uses genetic material, mRNA, to trick cells into producing bits of protein that look like pieces of the virus. The immune system learns to recognize and attack those bits and, in theory, would react fast to any actual infection.
Sahin has been described as a “modest and humble” person by colleagues, including Matthias Theobald, a fellow oncology professor at Mainz University, who has worked with him for two decades.
“Despite his achievements, he never changed from being incredibly humble and personable,” Matthias Kromayer, a board member of the MIG AG venture capital firm that has financially backed BioNTech, told Reuters on Monday.
Those attributes ring clear when listening to Sahin speak about the global race to stop the virus.
On Tuesday he said he believed the BioNTech/Pfizer vaccine “will not be the only vaccine” against Covid-19, noting that a number of Phase 3 vaccine trials are ongoing.
Sahin also said BioNTech’s goal, in cooperation with Pfizer, is to ramp up production of their vaccine candidate and that they hope to manufacture up to 1.3 billion doses by the end of 2021, if it receives authorization.
He reiterated that BioNTech and Pfizer plan to ask the US Food and Drug Administration to authorize emergency use of the vaccine, with that request coming perhaps as early as next week.
CNN’s Claudia Otto contributed to this report. Additional reporting by Reuters.